Expression patterns of microRNA-329 and its clinical performance in diagnosis and prognosis of breast cancer

Pihong Li*
Jienda Dong*
Xiang Zhou
Weijian Sun
He Huang
Sun Tong
Huang Weijian
Zhang Mingdong

Department of General Surgery, The Second Affiliated Hospital and Yuying Children’s Hospital of Wenzhou Medical University, Wenzhou, China

*These authors contributed equally to this work

Abstract: This study was aimed to assess the expression and clinical performance of microRNA-329 (miR-329) in breast cancer. We recruited 134 breast cancer patients and 70 healthy volunteers for this study. MiR-329 expression was estimated by quantitative real-time polymerase chain reaction. A receiver operating characteristic assay was performed to evaluate the diagnostic value of serum miR-329. In addition, the prognostic significance of miR-329 was evaluated through Kaplan–Meier survival and Cox regression analyses. According to quantitative real-time polymerase chain reaction, miR-329 expression was downregulated in cancerous samples compared with healthy and normal controls (P<0.01), and its expression in serum specimens positively correlated with its expression in tissue samples (R=0.493, P<0.001). The decreased expression of miR-329 correlated with lymph node metastasis (P=0.015) and TNM stage (P=0.003). A receiver operating characteristic curve with an area under the curve of 0.932 was constructed, indicating the high diagnostic accuracy of miR-329. From the survival and multivariate Cox assays, we found that downregulated miR-329 expression was associated with poor overall survival (log-rank P<0.001) and served as an independent prognostic factor (hazard ratio =2.987, 95% CI =1.681–5.308, and P<0.001). In silico analysis using The Cancer Genome Atlas confirmed that miR-329 expression was lower in breast cancer cases compared with normal controls (P<0.001) and could be an efficient biomarker for cancer patients. Down-regulated miR-329 expression was an effective diagnostic and prognostic biomarker, which could be used for targeted therapy in patients with breast cancer.

Keywords: miR-329, diagnosis, prognosis, breast cancer, target therapy

Introduction

Breast cancer is a worldwide health burden. It represents one of the most common malignancies among females and leads to a reduced quality of life in cancer patients.1 Statistics published by the World Health Organization indicate that there are ~70 newly diagnosed breast cancer cases among every 100,000 individuals annually in North America, Europe, and other countries.2 Some risk factors have been identified, such as lack of breastfeeding and dietary patterns, which are closely correlated with tumorigenesis of breast cancer.3-5 Therefore, many studies focusing on the treatment of breast cancer have been carried out. Although the mortality rate of this malignancy has been decreased thanks to the advances in therapeutic strategies, the prognoses and outcomes of breast cancer patients remain less than ideal.6,7 Previous data revealed that some patients with breast cancer present metastasis in the initial diagnosis, leading to poor outcomes and high mortality.8 Thus, improvement in diagnosis and prognosis is urgently needed for better management of breast cancer.
To improve cancer treatment, a great deal of cancer-related molecules and genes have been investigated to serve as useful biomarkers in various human malignancies. MicroRNAs (miRNAs), a series of small endogenous RNAs, are considered to be the crucial members among all the available molecular markers. They can regulate gene expression by binding to the 3′-untranslated regions of target mRNAs. MiRNAs have also been reported to be involved in a wide array of biological processes. In human cancers, aberrant expression levels of miRNAs have been detected, indicating that they may have special roles during tumor progression. Furthermore, the application of miRNAs has received increasing attention for their crucial clinical significance in cancers. Therefore, the identification of more functional miRNAs is critical for cancer treatment. MicroRNA-329 (miR-329) is clinically significant in some human cancers, such as glioblastoma and hepatocellular carcinoma. In addition, significantly downregulated miR-329 expression has been detected in breast cancer samples. Thus, we questioned whether there was a relationship between miR-329 expression and breast cancer diagnosis and prognosis.

In this study, we sought to assess the expression patterns of miR-329 in breast cancer samples and to investigate its correlation with tumor progression. In addition, the diagnostic and prognostic values of miR-329 were explored in patients with breast cancer.

Materials and methods

Patients and specimens collection

All the experimental procedures were approved by the Ethics Committee of Wenzhou Medical University. Informed consent was signed by each participant. A total of 134 patients who were histologically diagnosed with breast cancer at the Second Affiliated Hospital of Wenzhou Medical University between January 2006 and December 2010 were included in this study. In addition, 70 healthy volunteers were recruited in our research to act as healthy controls. All these healthy cases were selected from individuals who had routine physical examinations in the hospital without any history of malignancy. None of the breast cancer patients had ever received any therapy prior to the sampling. Venous blood samples were collected from all the participants and then centrifuged to obtain serum specimens. A total of 134 paired breast cancer tissues and adjacent normal breast tissues were obtained. The exosomes were isolated from the cell culture medium using ultracentrifugation and then stored at −80°C for further analyses.

Cell culture and exosomes collection

The human breast cancer cell lines MCF-7 and BT474 and a normal breast epithelial cell line MCF-10A were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum. Cell cultures were incubated in a humidified incubator with 5% CO₂ at 37°C. The exosomes were isolated from the cell culture medium using ultracentrifugation and then stored at −80°C for further analyses.

RNA extraction and qRT-PCR

The extraction of total RNA was performed by using TRIzol reagent® (Invitrogen, Carlsbad, CA, USA) following manufacturer’s instructions. The expression of miR-329 was measured using quantitative real-time polymerase chain reaction (qRT-PCR). Single-stranded cDNA, which was synthesized from RNA using the AMV reverse transcription system (Promega, Madison, WI, USA), was used as

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Association of miR-329 with the clinicopathological features of breast cancer patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Features</td>
<td>Total no (n=134)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
</tr>
<tr>
<td>≤50</td>
<td>50</td>
</tr>
<tr>
<td>&gt;50</td>
<td>84</td>
</tr>
<tr>
<td>Tumor size (cm)</td>
<td></td>
</tr>
<tr>
<td>≤3.0</td>
<td>55</td>
</tr>
<tr>
<td>&gt;3.0</td>
<td>79</td>
</tr>
<tr>
<td>LN metastasis</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>58</td>
</tr>
<tr>
<td>Positive</td>
<td>76</td>
</tr>
<tr>
<td>PR expression</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>65</td>
</tr>
<tr>
<td>Positive</td>
<td>69</td>
</tr>
<tr>
<td>ER expression</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>63</td>
</tr>
<tr>
<td>Positive</td>
<td>71</td>
</tr>
<tr>
<td>HER-2 expression</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>57</td>
</tr>
<tr>
<td>Negative</td>
<td>77</td>
</tr>
<tr>
<td>TNM</td>
<td></td>
</tr>
<tr>
<td>I–II</td>
<td>61</td>
</tr>
<tr>
<td>III–IV</td>
<td>73</td>
</tr>
</tbody>
</table>

Abbreviations: ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; LN, lymph node; miR-329, microRNA-329; PR, progesterone receptor.
Clinical significance of miR-329 in breast cancer

Results
Baseline characteristics of breast cancer patients and expression patterns of miR-329

A total of 134 histologically diagnosed breast cancer patients were included in this study with the average age of 52.52±16.28 years. Among these patients, 61 cases were diagnosed at a TNM I–II stage, while 73 cases were diagnosed at a TNM III–IV stage. Additionally, clinical characteristics of breast cancer patients are listed in Table 1.

The expression levels of miR-329 in the clinical samples were assessed by qRT-PCR. Serum miR-329 expression was downregulated in breast cancer patients compared with the healthy controls (P=0.0056, Figure 1A). Similarly, the expression of miR-329 was decreased in breast cancer tissues compared to normal controls (P=0.0068, Figure 1B). According to the Pearson correlation, we found that the serum miR-329 expression was positively correlated with tissue miR-329 expression levels (R=0.493, P<0.001, Figure 1C).

Expression levels of miR-329 in exosomes

In addition to serum and tissue expression patterns, miR-329 expression in exosomes collected from breast cancer cell culture medium was assessed in this study. The results shown in Figure 2 indicate that no significant miR-329 expression was detected between exosomes in breast cancer cells compared with normal breast cells (P>0.05).

Relationship between miR-329 expression and clinicopathological data of breast cancer patients

To assess whether miR-329 was involved in the progression of breast cancer, its association with clinical parameters was examined. The results of the chi-square test showed that breast cancer patients with positive lymph node metastasis had a lower miR-329 expression (P=0.015) and that the decreased miR-329 expression could be found in the patients with advanced TNM stages (P=0.003), indicating that miR-329 expression was associated with lymph node metastasis and TNM stage. Conversely, no relationship was detected between miR-329 expression and age, tumor size, and expression of progesterone receptor (PR), estrogen receptor (ER), or human epidermal growth factor receptor 2 (HER-2; P>0.05 for all; Table 1).

Clinical significance of miR-329 in breast cancer diagnosis and prognosis

Considering the deregulation of miR-329 in breast cancer samples, we examined its clinical performance in cancer patients. In the current study, an ROC curve with an area under the curve (AUC) of 0.932 was constructed (Figure 3), suggesting the high diagnostic accuracy of miR-329. At the optimal cutoff value of 0.745, the sensitivity and specificity were 87.1% and 89.6%, respectively. In addition, survival analysis based on expression of miR-329 was conducted for breast cancer patients. From the survival curves, we found that patients with lower miR-329 expression had
shorter survival times than those with high levels (log-rank
$P<0.001$, Figure 4). Furthermore, Cox regression analysis
was used to verify the prognostic value of miR-329. The
analysis revealed that the downregulated miR-329 expres-
sion was associated with a poor prognosis and acted as an
independent prognostic factor in patients with breast cancer.

Figure 1 Expression of miR-329 in serum and tissue specimens.
Notes: (A) miR-329 expression was downregulated in the serum samples of breast cancer patients compared with those of healthy controls ($^*P=0.0056$). (B) The expression of miR-329 was decreased in breast cancer tissues compared with adjacent normal tissues ($^*P=0.0068$). (C) The serum expression of miR-329 was positively correlated with the miR-329 tissue expression ($R=0.493$, $P<0.001$).

Abbreviation: miR-329, microRNA-329.

Figure 2 Expression of miR-329 in breast cancer cell-derived exosomes.
Note: No difference in miR-329 expression was found between breast cancer cells and normal breast cells ($P>0.05$).
Abbreviation: miR-329, microRNA-329.

Figure 3 ROC curve based on the expression of miR-329 for breast cancer patients.
Note: The AUC value was 0.932, indicating the high diagnostic value of miR-329 for patients with breast cancer.
Abbreviations: AUC, area under the curve; miR-329, microRNA-329; ROC, receiver operating characteristic.
Clinical significance of miR-329 in breast cancer

(hazard ratio = 2.987, 95% CI = 1.681–5.308, and \( P < 0.001 \), Table 2).

Validation of miR-329 expression and its clinical significance in TCGA

To further verify the expression and clinical significance of miR-329 in breast cancer, we used data collected from TCGA database. As shown in Figure 5, expression of miR-329 was significantly lower in breast cancer cases than in normal controls (\( P < 0.001 \)). Furthermore, the AUC of miR-329 was found to be 0.780 in the ROC analysis with a sensitivity of 72.6% and a specificity of 70.3% at the cutoff value of 0.987 (Figure 6A), which suggested the relatively high diagnostic accuracy of miR-329 in breast cancer patients. Moreover, the Kaplan–Meier survival analysis for the cancer patients revealed that low expression of miR-329 was correlated with poor overall survival (log-rank \( P = 0.033 \), Figure 6B).

Discussion

According to the statistics, breast cancer is considered a serious health risk for females, and it ranks as the most frequent malignancy in women in some countries.\(^{20,21}\) It is reported that numerous metastatic breast cancer cases in the USA occur in younger women.\(^{22}\) Thus, early detection is critically important for effective treatment of this malignancy. Thus far, considerable progress has been made in cancer treatment;\(^{23}\) however, the prognosis of breast cancer remains dismal, which is mainly due to aggressive biological factors.\(^{24}\) Therefore, diagnosis and prognosis of breast cancer need to be improved urgently. Accumulating data have revealed that a wide array of molecular biomarkers has a relatively high clinical value in various types of malignancies.\(^{25–27}\) Consequently, the poor outcomes of breast cancer emphasize the great need to identify novel diagnostic and prognostic biomarkers.

MiRNAs are considered an important class of the available biomarkers. Emerging studies have revealed that aberrant miRNA expression is involved in tumor progression.\(^{28}\) MiRNAs can suppress target gene expression, which may act as a crucial factor during tumor development.\(^{29}\) Thus, they are described as oncogenes or tumor suppressors that participate in the progression of tumors.\(^{30}\) For example, the tumor suppressor role of microRNA-205 has been observed in renal cell cancer tissues, and it was shown to suppress tumor cell progression.\(^{31}\) MicroRNA-584 was found to correlate with cell invasion and migration in thyroid carcinoma.\(^{32}\) Furthermore, the clinical significance of these miRNAs has also been highlighted in various cancers.\(^{33,34}\) MiR-329, an

![Figure 4](https://www.dovepress.com/)

**Figure 4** Kaplan–Meier survival analysis for breast cancer patients based on the difference in expression of miR-329.

**Note:** Decreased miR-329 expression correlated with poor overall survival of cancer patients (log-rank \( P < 0.001 \)).

**Abbreviation:** miR-329, microRNA-329.

### Table 2 Cox regression analysis for miR-329 in patients with breast cancer

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Univariate analysis</th>
<th>Multivariate analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>miR-329 (low vs high)</td>
<td>2.987</td>
<td>1.681–5.308</td>
</tr>
<tr>
<td>Age (year) (≥50 vs &lt;50)</td>
<td>0.849</td>
<td>0.505–1.428</td>
</tr>
<tr>
<td>Tumor size (cm) (&gt;3.0 vs ≤3.0)</td>
<td>1.163</td>
<td>0.713–1.896</td>
</tr>
<tr>
<td>Lymph node metastasis (positive vs negative)</td>
<td>0.957</td>
<td>0.589–1.554</td>
</tr>
<tr>
<td>PR expression (positive vs negative)</td>
<td>1.327</td>
<td>0.818–2.152</td>
</tr>
<tr>
<td>ER expression (positive vs negative)</td>
<td>0.956</td>
<td>0.592–1.544</td>
</tr>
<tr>
<td>HER-2 expression (positive vs negative)</td>
<td>0.804</td>
<td>0.497–1.302</td>
</tr>
<tr>
<td>TNM stage (III vs I–II)</td>
<td>1.319</td>
<td>0.796–2.187</td>
</tr>
</tbody>
</table>

**Note:** – indicates no related data.

**Abbreviations:** ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; HR, hazard ratio; miR-329, microRNA-329; PR, progesterone receptor.
extensively studied miRNA, has been investigated in some cancers and its clinical value was highlighted in previous studies. A study conducted by Kang et al has revealed that the expression of miR-329 was lower in breast cancer and associated with tumor cell proliferation, migration, and invasion, indicating its potential role for targeted therapy. However, the understanding of the clinical significance of miR-329 in breast cancer is limited. In the current study, the expression of miR-329 in breast cancer specimens was found to be abnormal when compared with the non-cancerous samples. Thus, we speculated that miR-329 may possess potential clinical value for patients with this malignant disease.

In the present study, expression levels of miR-329 were measured by qRT-PCR. The analysis showed that the expression of miR-329 was significantly lower in breast cancer serum specimens compared to healthy controls. Similarly, downregulated miR-329 expression was also detected in breast cancer tissues compared with the adjacent normal tissues. Moreover, serum miR-329 expression positively correlated with tissue miR-329 expression. In addition to the serum and tissue samples, we investigated miR-329 expression in breast cancer-derived exosomes and found no difference in miR-329 expression patterns between breast cancer cells and normal breast cells. According to the chi-square test, downregulated miR-329 expression was found to be influenced by positive lymph node metastasis and advanced TNM stage. Considering these data, miR-329 might function as a potential tumor suppressor and be involved in the development of breast cancer. In the study by Kang et al, expression of miR-329 was also found to be downregulated in breast cancer tissues and was reported to be involved in tumor progression via regulating the expression of p130Cas. Our results were in accordance with the previous data.

Given the potential tumor suppressor role of miR-329, we speculated that there were relationships between miR-329 expression and breast cancer diagnosis and prognosis. Thus, we used ROC analysis to examine its diagnostic value for
cancer patients, and we found that the decreased miR-329 expression was a highly sensitive and specific diagnostic marker for breast cancer. Additionally, Kaplan–Meier survival analysis was performed, and it was found that low levels of miR-329 expression were associated with poor overall survival of breast cancer patients. To further confirm its prognostic value, the multivariate Cox regression assay results demonstrated that the downregulated expression of miR-329 was an independent prognostic biomarker in patients with breast cancer. To further confirm the results above, the miR-329 expression levels and clinical information of 755 breast cancer patients were downloaded from the TCGA database. The analysis also showed that the expression of miR-329 was downregulated in breast cancer cases compared with the normal controls, and its expression could be used as a potential diagnostic and prognostic biomarker for patients with breast cancer.

Taken together, the data in our study revealed that the downregulated expression of miR-329 was correlated with the progression of breast cancer. Decreased miR-329 expression could serve as an efficient diagnostic and prognostic biomarker and may be used to improve targeted therapy for breast cancer. Although we provide evidence that miR-329 acts as a candidate biomarker for breast cancer, its molecular mechanisms remain unclear and need to be explored in further studies.

Disclosure

The authors report no conflicts of interest in this work.

References


